Amicus Therapeutics Shares Outstanding 2010-2022 | FOLD

Amicus Therapeutics shares outstanding from 2010 to 2022. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Amicus Therapeutics Annual Shares Outstanding
(Millions of Shares)
2021 271
2020 259
2019 240
2018 186
2017 153
2016 134
2015 110
2014 74
2013 51
2012 46
2011 35
2010 28
2009 23
Amicus Therapeutics Quarterly Shares Outstanding
(Millions of Shares)
2022-09-30 289
2022-06-30 292
2022-03-31 288
2021-12-31 271
2021-09-30 267
2021-06-30 266
2021-03-31 264
2020-12-31 259
2020-09-30 259
2020-06-30 258
2020-03-31 257
2019-12-31 240
2019-09-30 255
2019-06-30 238
2019-03-31 214
2018-12-31 186
2018-09-30 189
2018-06-30 189
2018-03-31 176
2017-12-31 153
2017-09-30 161
2017-06-30 143
2017-03-31 143
2016-12-31 134
2016-09-30 141
2016-06-30 129
2016-03-31 125
2015-12-31 110
2015-09-30 119
2015-06-30 100
2015-03-31 96
2014-12-31 74
2014-09-30 79
2014-06-30 67
2014-03-31 64
2013-12-31 51
2013-09-30 50
2013-06-30 50
2013-03-31 50
2012-12-31 46
2012-09-30 49
2012-06-30 47
2012-03-31 38
2011-12-31 35
2011-09-30 35
2011-06-30 35
2011-03-31 34
2010-12-31 28
2010-09-30 28
2010-06-30 28
2010-03-31 24
2009-12-31 23
2009-09-30 23
2009-06-30 23
2009-03-31 23
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $3.582B $0.306B
Amicus Therapeutics, Inc. is a global patient-centric biotechnology company engaged in the discovery, development and commercialization of a diverse set of novel treatments for patients living with rare metabolic diseases.?The company has one marketed medicine in its portfolio named Galafold which is the first and the only approved oral precision medicine for patients living with Fabry disease, having amenable genetic variants. Migalastat is a potent orally available inhibitor of alpha-Gal A.?The drug was granted an accelerated approval by the FDA for treating adult patients with a confirmed diagnosis of Fabry disease and an amenable genetic variant. Galafold is the first and only oral therapy approved in the EU for the long-term treatment of adolescents with Fabry disease.?The lead pipeline candidate in the company's portfolio is AT-GAA, a differentiated biologic for Pompe disease. The company has one gene-therapy program in its pipeline CLN3, a type of Batten disease, being evaluated in a phase I/II study.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $153.147B 9.34
GSK (GSK) United Kingdom $71.894B 8.95
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.086B 18.92
Ginkgo Bioworks Holdings (DNA) United States $3.531B 0.00
Myovant Sciences (MYOV) United Kingdom $2.613B 0.00
Arcus Biosciences (RCUS) United States $1.618B 24.29
Biohaven (BHVN) United States $1.266B 0.00
Emergent Biosolutions (EBS) United States $0.645B 5.07
ADC Therapeutics SA (ADCT) Switzerland $0.378B 0.00
Ambrx Biopharma (AMAM) United States $0.078B 0.00
Enzo Biochem (ENZ) United States $0.067B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.022B 0.00